Almotriptan

Almotriptan
Clinical data
Trade namesAxert, Almogran
Other namesLAS-31416; LAS31416
AHFS/Drugs.comMonograph
MedlinePlusa603028
License data
Routes of
administration
By mouth
Drug classSerotonin 5-HT1B, 5-HT1D, and 5-HT1F receptor agonist; Triptan; Antimigraine agent
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability70%
Protein binding35%
MetabolismLiver
Elimination half-life3–4 hours
Identifiers
IUPAC name
  • N,N-dimethyl-2- [5-(pyrrolidin-1-ylsulfonylmethyl)- 1H-indol-3-yl]-ethanamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H25N3O2S
Molar mass335.47 g·mol−1
3D model (JSmol)
SMILES
  • CN(C)CCc2c[nH]c3ccc(CS(=O)(=O)N1CCCC1)cc23
InChI
  • InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3 Y
  • Key:WKEMJKQOLOHJLZ-UHFFFAOYSA-N Y
  (verify)

Almotriptan, sold under the brand names Axert and Almogran among others, is a triptan medication used in the treatment of heavy migraine headache.[4][5][6][7]

Almotriptan was patented in 1992 and approved for medical use in 2000.[8] It was discovered and developed by Almirall-Prodesfarma.[7]

  1. ^ "Almotriptan tablet, film coated". DailyMed. Retrieved 17 February 2021.
  2. ^ "Axert- almotriptan malate tablet, coated". DailyMed. Retrieved 17 February 2021.
  3. ^ "Active substance: almotriptan" (PDF). List of nationally authorised medicinal products. Europeans Medicines Agency. 11 February 2021.
  4. ^ Rabasseda X (January 2001). "Almotriptan in the treatment of migraine". Drugs Today (Barc). 37 (1): 5–21. doi:10.1358/dot.2001.37.1.844180. PMID 12783094.
  5. ^ Cite error: The named reference PalaciosRabassedaCastaner1999 was invoked but never defined (see the help page).
  6. ^ Cite error: The named reference Holm_1999 was invoked but never defined (see the help page).
  7. ^ a b "Almotriptan". AdisInsight. 5 November 2023. Retrieved 28 July 2025.
  8. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 531. ISBN 9783527607495.